TAIWAN-LISTED ETF

CAPITAL NASDAQ BIOTECHNOLOGY INDEX EXCHANGE

00678

Public market and portfolio disclosure data. Latest market date: 2026-07-31.

41.04TWD+0.49
Latest closeTWD 41.04
Daily change+1.21%
Assets under managementTWD 342M
Trailing 12-month distribution yield
NAVTWD 40.64
Premium / discount0.98%
Beneficiaries1,820
Holdings dateJul 29, 2026

Period+5.75 (+16.29%)

Beneficial-owner trend

2026-03-23 → 2026-07-31-780 (-30.00%)

Fund profile

IssuerCapital Investment Trust
Listing dateJan 16, 2017
Management fee0.85%
Custody fee0.16%
Total expense ratio
Beneficiaries1,820
NAVTWD 40.64
Premium / discount0.98%

Latest distribution

No data is currently available.

Sector allocation

No data is currently available.

Top 10 holdings

SecurityPortfolio weight
AMGN US · AMGEN INC8.58%
VRTX US · VERTEX PHARMACEUTICALS INC8.05%
GILD US · GILEAD SCIENCES INC7.36%
REGN US · REGENERON PHARMACEUTICALS5.09%
RVMD US · REVOLUTION MEDICINES INC2.73%
ALNY US · ALNYLAM PHARMACEUTICALS INC2.72%
BIIB US · BIOGEN INC2.19%
ILMN US · ILLUMINA INC2.10%
RPRX US · ROYALTY PHARMA PLC- CL A1.86%
INCY US · INCYTE CORP1.79%
View holdings

Compare 00678 with another Taiwan ETF

Compare fees, returns, risk and disclosed portfolio overlap.

Taiwan ETF overview FAQ

What information is available on a Taiwan ETF overview page?

The page combines price and premium history, fund size, beneficial owners, fees, distributions, leading holdings and sector allocation from public Taiwan market disclosures.

What does a portfolio weight mean?

A portfolio weight is the percentage of the ETF allocated to a security. Larger positions generally have a greater influence on the ETF’s net asset value.

How current are the figures?

Market, holdings and distribution data update on different schedules. Use the date displayed in each section rather than assuming every figure has the same effective date.

Data note

Prices, portfolio holdings, fund statistics and distributions may have different effective dates. Data is for research and reference only and is not investment advice.